SCHEMBL18969110

SCHEMBL18969110

CCc1ccc(C2(C(F)(F)F)N=N2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.41
GABRA1 P14867 3/20 0.40
GABRB2 P47870 2/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.36
PDK2 Q15119 1/20 0.36
TP53 P04637 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
LMNA P02545 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP2A6 P11509 1/20 0.33
PLK1 P53350 1/20 0.33
POLB P06746 1/20 0.33
LPL P06858 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
DUSP3 P51452 1/20 0.33
ALDH1A1 P00352 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18969775 0.85 KIF11 (0.40) KIF11GABRA1GABRB2GABRG2GABRB3
SCHEMBL22698250 0.82 HRH3 (0.50) KIF11GABRA1GABRB2GABRG2GABRB3
SCHEMBL2535263 0.82 KIF11 (0.42) KIF11GABRA1GABRB2GABRG2GABRB3
SCHEMBL15892710 0.81 ESR1 (0.44) KIF11GABRA1GABRB2GABRG2GABRB3
SCHEMBL992639 0.80 GABRA1 (0.47) KIF11GABRA1GABRB2GABRG2GABRB3
SCHEMBL993831 0.80 KIF11 (0.41) KIF11GABRA1GABRB2GABRG2GABRB3
SCHEMBL18969109 0.79 GABRA1 (0.44) KIF11GABRA1GABRB2GABRG2GABRB3
SCHEMBL31751418 0.78 KIF11 (0.41) KIF11GABRA1GABRB2GABRG2GABRB3
SCHEMBL17600537 0.78 KIF11 (0.41) KIF11GABRA1GABRB2GABRG2GABRB3
Hydrochloric Acid SCHEMBL993872 0.78 KIF11 (0.44) KIF11GABRA1GABRG2GABRB3TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023225336-A1 MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 WO disclosed
WO-2023225320-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2023-11-23 WO disclosed
WO-2021018857-A1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS LES LABORATOIRES SERVIER (FR) 2021-02-04 WO disclosed
WO-2021018858-A1 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER LES LABORATOIRES SERVIER (FR) 2021-02-04 WO disclosed
WO-2017100525-A1 SUBSTITUTED BENZIMIDAZOLIUM, PYRIDO-IMIDAZOLIUM, OR PYRAZINO-IMIDAZOLIUM COMPOUNDS AS CHEMOTHERAPEUTICS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-06-15 WO disclosed